Results 81 to 90 of about 155 (115)
MedicineBackground: The efficacy of esketamine nasal spray for treatment-resistant depression remains controversial. This systematic review and meta-analysis was conducted to explore the influence of esketamine nasal spray on treatment efficacy for treatment-resistant depression.
Yannan Ouyang, Juan Li
openaire +2 more sources
Drugs - Real World OutcomesBackground This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US).
Lisa Harding +6 more
doaj +1 more source
Esketamine nasal spray approved for treatment-resistant depression
American Journal of Health-System Pharmacy, 2019 openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
New England Journal of Medicine, 2023In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation ...
Reif, Andreas +21 more
openaire +3 more sources
Safety of Esketamine Nasal Spray Is Consistent With Clinical Reports
Psychiatric Newsexaly +2 more sources
Sustained improvement in depression seen in study of esketamine nasal spray
The Brown University Psychopharmacology Update, 2023Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported.
openaire +1 more source
Longer course of esketamine nasal spray benefits initial treatment nonresponders
The Brown University Psychopharmacology Update, 2021Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found.
openaire +1 more source
Esketamine nasal spray offers rapid benefit in patients at risk of suicide
The Brown University Psychopharmacology Update, 2020Esketamine nasal spray acted rapidly to reduce depressive symptoms in a 4‐week study of patients with major depressive disorder and active suicidal ideation with intent. The results offer promise for emergency treatment of a condition for which there is currently no approved therapeutic.
openaire +1 more source
Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression
The Journal of Clinical PsychiatryBackground: Under a risk evaluation and mitigation strategy program, esketamine nasal spray CIII requires self administration at a certified treatment center. Our objective was to identify factors associated with esketamine initiation and continuation.Methods: A retrospective observational cohort study was conducted among US adults who met treatment ...
Kruti, Joshi +4 more
openaire +2 more sources